
News|Videos|October 31, 2023
Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib
Author(s)Martin Dietrich, MD, PhD
Martin Dietrich, MD, PhD, presents key data from the phase 3 MARIPOSA-2 study, which investigated amivantamab plus chemotherapy, with or without lazertinib, versus chemotherapy in patients with EGFR-mutated advanced NSCLC who experienced disease progression on osimertinib.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5



































